New York Man Alleges that Diabetes Medication Actos Caused Bladder Cancer in Newly Filed Lawsuit
Parker Waichman LLP has filed a lawsuit on behalf of a man who developed bladder cancer, allegedly due to the use of Actos (pioglitazone). Actos is a type 2 diabetes medication that has been linked to bladder cancer in a number of studies. According to a recent report in Consumer Reports, the risks of taking Actos outweigh the benefits for most patients.
New York, New York (PRWEB) September 21, 2012
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a man who developed bladder cancer after taking Actos. The lawsuit alleges that Actos caused the cancer and claims that the Defendants, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc. f/k/a, Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company, failed to warn about the risks of the drug. The suit was filed on September 17th in the U.S. District Court for the Western District of Louisiana (Case No. 6:12-cv-2451), where it is one of many cases pending in the multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299).
According to the Complaint, the Plaintiff began taking Actos between 2005 and 2007, and developed bladder cancer in 2006. The suit alleges that taking Actos caused the bladder cancer, and is seeking compensation for injuries and damages. The lawsuit is claiming severe mental and physical pain and suffering, permanent injuries and emotional distress, economic loss due to medical expenses and living related expenses due to a new lifestyle on behalf of the Plaintiffs. The suit also alleges that the Defendants knew that Actos could cause bladder cancer, and concealed this knowledge from the Plaintiff, other consumers and the medical community.
There is a substantial amount of research supporting the link between Actos and bladder cancer. Last June, the U.S. Food and Drug Administration (FDA) warned that using the drug for more than one year could significantly increase these risks. Last month, the Journal of the National Cancer Institute published a study showing that long-term use of Actos and other thiazolidinediones (TZDs) can increase the likelihood of developing bladder cancer. In July, a study in the Canadian Medical Association Journal found that patients taking Actos had a 22 percent increased risk.
The FDA recently approved several generic versions of Actos. According to Consumer Reports, Actos should only be a last resort treatment, whether or not it is generic. The report said that with options such as metformin, glymepiride and glypizide available, there is little reason for patients to expose themselves to the risks of Actos. [http://news.consumerreports.org/health/2012/08/new-generic-diabetes-drug-actos-is-one-bargain-to-avoid.html
Parker Waichman LLP continues to offer free legal consultations to victims of Actos. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting the firm’s page at yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebactosbladdercancer/092012/prweb9931842.htm